Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
DPP-4 Inhibitors Archives
Print | Email | Share | Comments (0)

First-World Type 2 Drug Market to Reach $47 Billion by 2022


Oct 18, 2013

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022.

The firm, Decision Resources, says increased sales in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom, will come from both an increase in the type 2 patient population and the introduction of new drugs.

The report says that proprietary DPP-4 inhibitors, such as Merck's Januvia (sitagliptin), will continue lead the market in terms of overall share through 2022. However, Decision Resources predicts that sales in the DPP-4 inhibitor category will peak at $14 billion by 2021 then erode in the wake of the introduction of generic versions.

A newer drug category, the SGLT-2 inhibitors, which work by expelling glucose through the kidneys, are predicted to be the fastest growing class of type 2 drugs. Examples of the class include Invokana from Johnson & Johnson, and Forxiga from AstraZeneca/Bristol-Myers.

Another contributor to drug sales growth will be from attempts by pharmaceutical companies to distinguish their products by combining current therapies into novel combinations, such as long-acting insulin and GLP-1 receptor agonist (such as Byetta and Victoza).


Categories: Byetta, Decision Resources, DPP-4 Inhibitors, Forxiga, GLP-1 Receptor Agonist, Invokana, Januvia, SLGT-2 Inhibitors, Type 2 Drugs, Victoza



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.